Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Enhanced Genomics extends Series A funding to USD $19 million to drive development of therapeutics pipeline
_↗ enhancedgenomics.com
News Image

An additional $19 million has been secured in Series A funding for the Cambridge, UK-based biotechnology company, Enhanced Genomics The additional investment comes from BGF, Parkwalk, and Meltwind and will be used to accelerate the development of the company’s therapeutics pipeline, particularly focusing on autoimmune conditions like inflammatory bowel disease. This funding will also allow Enhanced Genomics to expand its reach through strategic partnerships with other pharmaceutical and biotech companies, leveraging its proprietary technology for long-term growth. The additional investment comes from BGF, Parkwalk, and Meltwind and will be used to accelerate the development of the company’s therapeutics pipeline, particularly focusing on autoimmune conditions like inflammatory bowel disease. This funding will also allow Enhanced Genomics to expand its reach through strategic partnerships with other pharmaceutical and biotech companies, leveraging its proprietary technology for long-term growth.

Enhanced Genomics specializes in using its unique 3D multi-omics platform to identify genetically validated drug targets for complex, common diseases. This platform and its cell type-specific atlas can define the causal biology of diseases on a genome-wide scale, translating vast amounts of data into actionable insights. This process aims to increase the success rate of drug development and significantly reduce the time and cost involved. By providing strong genetic evidence for new drug targets, Enhanced Genomics believes it can lead the next major shift in the pharmaceutical industry. The company's founders have pioneered technology to map 3D interactions across the entire genome and integrate this with comprehensive multi-omics data, giving them the ability to decipher the causal biology of complex genetic diseases and potentially develop new blockbuster therapies. The company is actively pursuing its own in-house discovery and development programs while also seeking partnerships to help others with their drug discovery initiatives. The ultimate goal is to identify new, high-confidence therapeutic targets for common diseases where there is a significant unmet medical need.

Log In
Sign Up